Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive

Myriam Alvarez3.32K FollowersFollow5ShareSavePlay(10min)CommentsSummaryQ32 Bio is now largely a single-asset story centered on Bempikibart in alopecia areata, with mid-2026 topline data as the key catalyst.Management sold ADX-097 to Akebia, which brings milestone and royalty payments as an extra while concentrating its efforts on Bempikibart's R&D.Bempikibart's prior data and ongoing OLE data suggest durable responses and possible remission. This keeps my long-term alopecia areata thesis alive for QTTB.While I reckon cash burn, dilution, and timeline risks remain, I ultimately feel QTTB could become a long-term winner on AA for patient investors.VLG/iStock via Getty Images Q32 Bio Inc. (QTTB) is a clinical-stage biotech that develops Bempikibart, which is a candidate for treating alopecia areata (AA). This drug is in Phase 2a of the SIGNAL-AA trial and has reported positive data from previous studies. BempikibartThis article was written byMyriam Alvarez3.32K FollowersFollowMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking Alpha. Our analyses are conducted independently, and we adhere to Seeking Alpha's Shared Association Guidelines.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.